Johnson & Johnson Says Their Vaccine Is Effective With Canada Expecting 38 Million Doses

It's been 72% effective in the U.S. at preventing moderate to severe cases.

COVID-19 Vaccine Canada: Johnson & Johnson Says Theirs Is Effective

Senior Creator

With the Johnson & Johnson COVID-19 vaccine, Canada is expecting to receive up to 38 million doses and the company has now said it's effective.

An interim analysis of the vaccine's phase three trial was released on January 29 about its effectiveness and protection along with a brief timeline.

Editor's Choice:The Polar Vortex Is Sinking & Bringing 'The Coldest Air Of The Season' To Eastern Canada

38 million doses Canada could receive

Johnson & Johnson said that its vaccine is 72% effective in the U.S. and 66% effective overall in preventing moderate to severe cases of COVID-19 28 days after vaccination.

It's also 85% effective overall in preventing severe disease and showed "complete protection" against COVID-19-related hospitalization and death also at the 28-day mark.

Unlike the Pfizer and Moderna vaccines, this one requires a single dose.

The company is planning on filing for emergency use authorization in the U.S. sometime in early February and expects to have the doses ready to ship right after it's obtained.

There's no word yet on if or when approval from Health Canada for this vaccine could happen.

Canada has secured doses from Pfizer, Moderna, Johnson & Johnson, Sanofi and GlaxoSmithKline, Medicago, Novavax and AstraZeneca.

That means the country is expected to get up to 398 million doses.

Health Canada has a robust website with all the latest information on the vaccine and can answer any questions you may have. Click here for more information.